- 1.
Gibbons LW, Mitchell TL, Gonzalez V. The safety of exercise testing. Prim Care 1994; 21: 611 – 29.
- 2.
Pennel DJ, Prvulovich E. Nuclear cardiology. London: British Nuclear Medicine Society, 1995.
- 3.
Abreu A, Mahmarian JJ, Nishimura S, Boyce TM, Verani MS. Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol 1991; 18: 730 – 5.
- 4.
Pennell DJ, Mahmood S, Ell PJ, Underwood SR. Bradycardia progressing to cardiac arrest during adenosine thallium myocardial perfusion imaging in occult sino-atrial disease. Eur J Nucl Med 1994; 21: 170 – 2.
- 5.
Zhu YY, Chung WS, Botvinick EH, Dae MW, Lim AD, Ports TA et al. Dipyridamole perfusion scintigraphy: the experience with its application in one hundred seventy patients with known or suspected unstable angina. Am Heart J 1991; 121: 33 – 43.
- 6.
Mahmarian JJ, Verani MS. Myocardial perfusion imaging during pharmacologic stress testing. Cardiol Clin 1994; 12: 223 – 45.
- 7.
Rootwelt K. Nukleær medisin. Oslo: Universitetsforlaget, 1995.
- 8.
Stratmann HG, Williams GA, Wittry MD, Chaitman BR, Miller DD. Exercise technetium-99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. Circulation 1994; 89: 615 – 22.
- 9.
Fagan LF jr., Shaw L, Kong BA, Caralis DG, Wiens RD, Chaitman BR. Prognostic value of exercise thallium scintigraphy in patients with good exercise tolerance and a normal or abnormal exercise electrocardiogram and suspected or confirmed coronary artery disease. Am J Cardiol 1992; 69: 607 – 11.
- 10.
Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527 – 60.
()